NERV (Minerva Neurosciences) Beginning Cash Position: $82.40 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NERV Minerva Neurosciences Inc NERV
32 GF Score
Price $4.33
! 1 Warning Sign
View Full Analysis

What is Minerva Neurosciences Beginning Cash Position?

Minerva Neurosciences NERV +7.33% 32 Beginning Cash Position is $82.40 Mil as of Mar. 2026. GuruFocus rates NERV with a GF Score™ of 32/100. The stock has 1 warning sign investors should review.

Minerva Neurosciences's Beginning Cash Position for the quarter that ended in Mar. 2026 was $82.40 Mil.

Minerva Neurosciences's quarterly Beginning Cash Position increased from Sep. 2025 ($15.30 Mil) to Dec. 2025 ($86.88 Mil) but then declined from Dec. 2025 ($86.88 Mil) to Mar. 2026 ($82.40 Mil).

Minerva Neurosciences's annual Beginning Cash Position increased from Dec. 2023 ($36.19 Mil) to Dec. 2024 ($41.01 Mil) but then declined from Dec. 2024 ($41.01 Mil) to Dec. 2025 ($21.46 Mil).

Minerva Neurosciences Beginning Cash Position Related Terms

Minerva Neurosciences Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Minerva Neurosciences's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Minerva Neurosciences Beginning Cash Position Chart

Minerva Neurosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.46 60.86 36.19 41.01 21.46

Minerva Neurosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.46 17.39 15.30 86.88 82.40
NERV
32GF Score
Minerva Neurosciences Inc NERV
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Minerva Neurosciences Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $82.40 Mil mean?
Minerva Neurosciences (NERV) has a Beginning Cash Position of $82.40 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Minerva Neurosciences and its competitors.
Is Minerva Neurosciences' Beginning Cash Position too high?
Minerva Neurosciences' current Beginning Cash Position is $82.40 Mil. Overall, Minerva Neurosciences has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Minerva Neurosciences' Beginning Cash Position compare to TTRX and WHWK?
Minerva Neurosciences' Beginning Cash Position of $82.40 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Minerva Neurosciences and its competitors. Minerva Neurosciences's current Beginning Cash Position is $82.40 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minerva Neurosciences stock overvalued right now?
Minerva Neurosciences (NERV) has a current Beginning Cash Position of $82.40 Mil. The current Beginning Cash Position is $82.40 Mil. Minerva Neurosciences' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Minerva Neurosciences (NERV), the current Beginning Cash Position is $82.40 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Minerva Neurosciences Business Description

Other Exchanges 4MNA:Germany
Address 1500 District Avenue, Burlington, MA, USA, 01803
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.
32GF Score

Get the complete analysis for NERV

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.33
Price